- Home
- CVAC vs AVBP Comparison
CVAC vs AVBP Comparison
Compare CVAC & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- AVBP
- Stock Information
- Founded
- CVAC 2000
- AVBP 2021
- Country
- CVAC Germany
- AVBP United States
- Employees
- CVAC N/A
- AVBP N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- AVBP
- Sector
- CVAC Health Care
- AVBP
- Exchange
- CVAC Nasdaq
- AVBP NYSE
- Market Cap
- CVAC 818.8M
- AVBP 879.2M
- IPO Year
- CVAC 2020
- AVBP 2024
- Fundamental
- Price
- CVAC $3.30
- AVBP $27.07
- Analyst Decision
- CVAC Hold
- AVBP Strong Buy
- Analyst Count
- CVAC 3
- AVBP 4
- Target Price
- CVAC $10.00
- AVBP $38.00
- AVG Volume (30 Days)
- CVAC 617.5K
- AVBP 143.3K
- Earning Date
- CVAC 11-12-2024
- AVBP 03-04-2025
- Dividend Yield
- CVAC N/A
- AVBP N/A
- EPS Growth
- CVAC N/A
- AVBP N/A
- EPS
- CVAC N/A
- AVBP N/A
- Revenue
- CVAC $70,565,734.00
- AVBP N/A
- Revenue This Year
- CVAC $742.57
- AVBP N/A
- Revenue Next Year
- CVAC N/A
- AVBP N/A
- P/E Ratio
- CVAC N/A
- AVBP N/A
- Revenue Growth
- CVAC 75.11
- AVBP N/A
- 52 Week Low
- CVAC $2.22
- AVBP $14.35
- 52 Week High
- CVAC $5.28
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- CVAC 39.12
- AVBP 49.67
- Support Level
- CVAC $3.53
- AVBP $25.89
- Resistance Level
- CVAC $3.72
- AVBP $28.12
- Average True Range (ATR)
- CVAC 0.18
- AVBP 1.48
- MACD
- CVAC -0.06
- AVBP -0.06
- Stochastic Oscillator
- CVAC 10.96
- AVBP 33.69
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.